Progressive multifocal leukoencephalopathy: epidemiology and spectrum of predisposing conditions.


Journal

Brain : a journal of neurology
ISSN: 1460-2156
Titre abrégé: Brain
Pays: England
ID NLM: 0372537

Informations de publication

Date de publication:
05 01 2023
Historique:
received: 12 02 2022
revised: 15 05 2022
accepted: 20 06 2022
pubmed: 3 7 2022
medline: 11 1 2023
entrez: 2 7 2022
Statut: ppublish

Résumé

Population-based data on the epidemiology of progressive multifocal leukoencephalopathy, its predisposing conditions and mortality rate are lacking, although such data are crucial to raise awareness among clinicians and to lay foundations for future therapeutic trials in immunomodulating therapies. In our study, patients were identified by interrogating the French national healthcare reimbursement database from 1 January 2008 to 31 December 2017, using progressive multifocal leukoencephalopathy International Classification of Diseases code and a patient's selection algorithm. Overall incidence rate, 1-year all-cause mortality rate and survival patterns were calculated, and factors associated with death were identified using a multivariate Cox proportional hazards regression model. Our cohort is the largest to date, comprising 584 patients with incident progressive multifocal leukoencephalopathy. The overall incidence in France from 2010 to 2017 was stable during the study period at 0.11 per 100 000 person-years, 95% confidence interval [0.10-0.12]. Predisposing diseases were HIV infection (43.7%), followed by haematological malignancies (21.9%), chronic inflammatory diseases (20.2%), solid organ transplantation (4.3%), solid neoplasm (4.1%) and primary immune deficiency (1.5%). The 1-year mortality rate was 38.2%, with a 95% confidence interval (34.2-42.2). In multivariate analysis, factors independently associated with death were older age [adjusted hazard ratio 0.33 (0.20-0.53) for patients aged 20 to 40 compared with patients aged over 60], male gender [adjusted hazard ratio 0.73 (0.54-0.99) for females compared with males] and predisposing immunosuppressive disease, with the highest risk for solid neoplasms [adjusted hazard ratio 4.34 (2.25-8.37)], followed by haematological malignancies [adjusted hazard ratio 3.13 (1.85-5.30)] and HIV infection [adjusted hazard ratio 1.83 (1.12-3.00)], compared with chronic inflammatory diseases. Immune reconstitution inflammatory syndrome was notified in 7.0% of patients. In conclusion, incidence of progressive multifocal leukoencephalopathy is stable in France, and HIV infection remains the main predisposing disease. This large-size cohort uncovers a higher risk of mortality for male patients compared to females, and the worst prognosis for patients with solid neoplasm, while prognosis in patients with haematological malignancies appeared less dismal than in previous studies.

Identifiants

pubmed: 35779271
pii: 6627590
doi: 10.1093/brain/awac237
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

349-358

Informations de copyright

© The Author(s) 2022. Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Auteurs

Marine Joly (M)

Department of Infectious and Tropical Diseases, Toulouse University Hospital Center, Toulouse 31300, France.

Cécile Conte (C)

Department of Medical Pharmacology, CIC 1436, Toulouse University Hospital Center, Toulouse 31300, France.

Charles Cazanave (C)

Department of Infectious and Tropical Diseases, Bordeaux University Hospital Center, Bordeaux 33300, France.

Vincent Le Moing (V)

Department of Infectious and Tropical Diseases, Montpellier University Hospital Center, Montpellier 34295, France.

Pierre Tattevin (P)

Department of Medical Intensive Care and Infectious Diseases, Rennes University Hospital Center, Rennes 35000, France.

Pierre Delobel (P)

Department of Infectious and Tropical Diseases, Toulouse University Hospital Center, Toulouse 31300, France.
Institut Toulousain des Maladies Infectieuses et Inflammatoires (Infinity) INSERM UMR1291, CNRS UMR5051, University of Toulouse III, Toulouse 31300, France.

Agnès Sommet (A)

Department of Medical Pharmacology, CIC 1436, Toulouse University Hospital Center, Toulouse 31300, France.

Guillaume Martin-Blondel (G)

Department of Infectious and Tropical Diseases, Toulouse University Hospital Center, Toulouse 31300, France.
Institut Toulousain des Maladies Infectieuses et Inflammatoires (Infinity) INSERM UMR1291, CNRS UMR5051, University of Toulouse III, Toulouse 31300, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH